Edesa Biotech, Inc. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 88/100
What the filing says
Edesa Biotech granted exclusive rights to paridiprubart in Japan to KYORIN Pharmaceutical for ARDS treatment. Edesa receives $12M upfront plus up to $134M in development/regulatory/sales milestones and double-digit tiered royalties on net sales. Edesa retains all rights outside Japan; Kyorin gains right of first negotiation for AKI and non-exclusive negotiation rights for other indications.
Why this rating
Deal value ($140M potential) exceeds company market cap (≈$14M) by 10x; represents major validation, cash injection, and de-risks lead asset commercialization pathway.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.32 ▼ 36.75% | at our read · unknown $3.67 | +10 min · unknown $3.18 ▼ 13.35% | +30 min · unknown $3.42 ▼ 6.81% | +1 hr · unknown $2.87 ▼ 21.80% | +4 hrs · unknown $2.92 ▼ 20.41% |
The stock had already moved +58.09% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.